Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) have been assigned a consensus rating of “Hold” from the eleven analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, one has given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $14.43.
A number of equities analysts recently issued reports on the company. BidaskClub cut Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 18th. Stifel Nicolaus upgraded Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the stock from $18.00 to $21.00 in a report on Thursday, February 22nd. ValuEngine upgraded Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, February 23rd. Finally, TheStreet cut Momenta Pharmaceuticals from a “c-” rating to a “d” rating in a report on Tuesday, May 8th.
In related news, SVP Young Kwon sold 15,089 shares of the stock in a transaction on Thursday, April 19th. The stock was sold at an average price of $20.90, for a total value of $315,360.10. Following the completion of the sale, the senior vice president now directly owns 147,411 shares of the company’s stock, valued at approximately $3,080,889.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Craig A. Wheeler sold 1,772 shares of the stock in a transaction on Thursday, May 10th. The shares were sold at an average price of $21.86, for a total value of $38,735.92. Following the completion of the sale, the chief executive officer now directly owns 198,987 shares of the company’s stock, valued at $4,349,855.82. The disclosure for this sale can be found here. Insiders sold a total of 174,558 shares of company stock valued at $3,512,669 over the last three months. 4.40% of the stock is currently owned by insiders.
Shares of Momenta Pharmaceuticals opened at $21.70 on Friday, according to Marketbeat Ratings. Momenta Pharmaceuticals has a 12-month low of $20.90 and a 12-month high of $21.90. The firm has a market capitalization of $1.63 billion, a P/E ratio of -18.08 and a beta of 1.63.
Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.19). Momenta Pharmaceuticals had a negative return on equity of 28.56% and a negative net margin of 88.77%. The firm had revenue of $4.85 million during the quarter, compared to the consensus estimate of $15.63 million. During the same quarter in the prior year, the business earned ($0.46) earnings per share. Momenta Pharmaceuticals’s revenue for the quarter was down 81.8% on a year-over-year basis. analysts predict that Momenta Pharmaceuticals will post -1.34 earnings per share for the current year.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.